Short Interest in Journey Medical Co. (NASDAQ:DERM) Grows By 14.8%

Journey Medical Co. (NASDAQ:DERM) was the recipient of a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 76,800 shares, a growth of 14.8% from the December 31st total of 66,900 shares. Based on an average daily volume of 108,900 shares, the short-interest ratio is presently 0.7 days. Currently, 0.8% of the shares of the company are short sold.

Institutional Trading of Journey Medical

A number of institutional investors have recently bought and sold shares of the business. PVG Asset Management Corp boosted its holdings in Journey Medical by 5.7% in the 3rd quarter. PVG Asset Management Corp now owns 167,545 shares of the company’s stock valued at $947,000 after purchasing an additional 9,005 shares during the period. Geode Capital Management LLC boosted its holdings in Journey Medical by 13.5% in the 3rd quarter. Geode Capital Management LLC now owns 108,435 shares of the company’s stock valued at $613,000 after purchasing an additional 12,882 shares during the period. ORG Wealth Partners LLC bought a new stake in Journey Medical in the 3rd quarter valued at about $110,000. Kovitz Investment Group Partners LLC bought a new stake in Journey Medical in the 3rd quarter valued at about $66,000. Finally, Nwam LLC acquired a new position in shares of Journey Medical in the 3rd quarter valued at approximately $59,000. Institutional investors own 7.25% of the company’s stock.

Journey Medical Stock Performance

NASDAQ DERM opened at $4.55 on Monday. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 1.81. The company has a market capitalization of $95.05 million, a P/E ratio of -4.84 and a beta of 1.00. Journey Medical has a 12-month low of $2.85 and a 12-month high of $6.89. The firm has a 50-day moving average price of $4.53 and a two-hundred day moving average price of $5.06.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.